MULTIPLE MYELOMA

Final overall survival results of the phase 2 ELOQUENT-3 trial reveal benefit with elotuzumab plus pomalidomide, and dexamethasone in patients with relapsed/refractory multiple myeloma.

During a Targeted Oncology case-based roundtable event, Peter Forsberg, MD and Robert M. Rifkin, MD, FACP, discussed the trials supporting the use of BCMA-targeted agents for relapsed/refractory multiple myeloma.

The combination of talquetamab and daratumumab has the potential to demonstrate synergistic clinical activity, and preclinical studies have shown that the addition of daratumumab enhanced talquetamabmediated lysis of multiple myeloma cells.

In an interview with Targeted OncologyTM Nina Shah, MD, discusses the findings from several trials that show the efficacy of daratumumab for patients with multiple myeloma.

Jesus G. Berdeja, MD, discusses the potential of chimeric antigen receptor T-cell therapy to be approved for earlier lines of treatment in multiple myeloma.

Results from the interim analysis of phase 3 KarMMa-3 study indicate improvement in progression-free survival with idecabtagene vicleucel compared with standard combination regimens, as well as better responses.

With a median progression-free survival of 46.2 months in the RVD-alone group and 67.5 months in the transplantation group, lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplantation extends overall survival in patients with newly diagnosed multiple myeloma.

During a Targeted Oncology live virtual event, Caitlin Costello, MD, discussed treatment of a patient who previously received systemic therapy and autologous stem cell transplant for multiple myeloma. This is the second of 2 articles based on this event.

During a Targeted Oncology case-based roundtable event, Larry D. Anderson, MD, PhD, discussed the results of the DREAMM-2 trial and management of belantamab mafodotin for patients with multiple myeloma.

During a live virtual event, Caitlin Costello, MD, discussed the rationale for choosing a triplet or quadruplet regimen for patients with transplant-eligible newly diagnosed multiple myeloma.

Paul G. Richardson, MD, discusses the unmet medical needs that still exist in the multiple myeloma space.

The FDA has granted breakthrough therapy designation to talquetamab for the treatment of previously-treated adult patients with relapsed or refractory multiple myeloma based on positive results from the phase 1/2 MonumenTAL-1 study.

During a Targeted Oncology case-based roundtable event, Peter Voorhees, MD, discussed therapy options and transplant eligibility for patients with multiple myeloma.

Jesus G. Berdeja, MD, director of multiple myeloma research at Sarah Cannon Research Institute and hematology specialist at Tennessee Oncology, discusses the results of the CARTITUDE-1 trial for chimeric antigen receptor T-cell therapy with the newly-approved agent ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

During a Targeted Oncology case-based roundtable event, Binod Dhakal, MD, MS, discussed key data related to the treatment of newly diagnosed multiple myeloma.

In elderly frail patients with relapsed/refractory multiple myeloma, treatment with ixazomib plus daratumumab achieved favorable response rates.

At the 2022 ASCO Annual Meeting findings from the phase, 3 DETERMINATION trial showed off the survival benefit when adding autologous stem cell transplant and lenalidomide maintenance after RVd treatment for patients with newly diagnosed multiple myeloma.

Among patients with newly diagnosed, transplant-eligible myeloma treated in a phase 2 study, induction and consolidation with daratumumab plus the RVd regimen outperformed RVd alone in terms of minimal residual disease and progression-free survival.

During a Targeted Oncology case-based roundtable event, Robert A. Vescio, MD, discussed the results of several key trials related to new treatments for patients with transplant-eligible multiple myeloma.

During a Targeted Oncology case-base roundtable event, Jesus G. Berdeja, MD, moderated a discussion around a 55-year-old Black man with late-stage multiple myeloma being treated in a rural community.

Paul G Richardson, MD, discusses the ways treatment approaches for patients with multiple myeloma has changed over the past few years.

In the phase 3 IKEMA study, isatuximab added to carfilzomib and dexamethasone improved progression-free survival in patient with relapsed multiple myeloma.

Findings from a phase 1 study of CART-ddBCMA cells exemplify their safety and ability to induce durable responses in patients with relapsed or refractory multiple myeloma.

Adam Cohen, MD, discussed the recent updates and advancements in BCMA-directed therapies for multiple myeloma.

Before closing out his discussion on newly diagnosed multiple myeloma, Ajay K. Nooka, MD, MPH, FACP, emphasizes the continued role of transplantation in this setting.